Phase I dose escalation study of lestaurtinib in patients with myelofibrosis

Despite extensive prior clinical investigation in acute leukemia (60 – 100 mg), dose finding studies have not yet established a true maximum tolerated dose (MTD) for the oral multi-kinase inhibitor lestaurtinib in hematologic malignancies. We performed a multicenter, investigator initiated, phase I...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Leuk Lymphoma
Asıl Yazarlar: Hexner, Elizabeth O, Mascarenhas J, John, Prchal, Josef, Roboz, Gail J, Baer, Maria R, Ritchie, Ellen K, Leibowitz, David, Demakos, Erin P, Miller, Crystal, Siuty, James, Kleczko, Jill, Price, Leah, Jeschke, Grace, Weinberg, Rona, Basu T, Titiksha, Pahl, Heike L, Orazi, Attilio, Najfeld, Vesna, Marchioli, Roberto, Goldberg, Judith D, Silverman, Lewis R, Hoffman, Ronald
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5665563/
https://ncbi.nlm.nih.gov/pubmed/25563429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2014.1001986
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller